Clinical trials for VAL-083

VAL-083 is a structurally unique, "first-in-class", small-molecule chemotherapeutic.

The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the

For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More Information

The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and

For Patients With Recurrent Malignant Glioma: More Information
Targeting Various Forms of Cancer

Targeting Various Forms of Cancer

VAL-083 demonstrates activity in a wide range of cancer cell lines, including pediatric and adult GBM cell lines and GBM cancer stem cells.

Do You Have Questions?

Contact us to learn more about our trials or VAL-083.

The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.